DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Idiopathic Pulmonary Fibrosis | Landscape & Forecast | Disease Landscape & Forecast

Idiopathic Pulmonary Fibrosis | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Although a rare disease, idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (ILDs). Characterized by an irreversible loss of lung function, it is associated with a high morbidity and mortality rate; most patients die within three to five years following diagnosis. The etiology of IPF is unclear, but accumulating evidence suggests that it arises as a result of epithelial injury followed by abnormal wound healing. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev)—setting the stage for fierce competition in the IPF therapy market. We explore this evolving space, analyzing the clinical and commercial outlook for pirfenidone and nintedanib and FibroGen’s emerging IV-administered IPF therapy pamrevlumab. We examine current medical practice and identify areas of pressing unmet need in the treatment of IPF. We also assess different market scenarios in which Galapagos’s GLPG-1690, an oral autotaxin inhibitor, is approved as a monotherapy or as an add-on therapy for IPF.


  • How will the size of the IPF population change through 2028? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
  • How do interviewed experts view the clinical profiles of Esbriet and Ofev, and what factors drive or constrain their use? What are the most pressing unmet clinical needs in the management of IPF, according to experts?
  • Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market positions of Ofev and Esbriet? What is the commercial potential of a new monotherapy or an add-on therapy for IPF?

Table of contents

  • Disease Landscape & Forecast
    • Commercial Outlook
      • Key Findings
      • Drivers and Constraints
        • What Factors Are Driving the Market for Idiopathic Pulmonary Fibrosis?
        • What Factors Are Constraining the Market for Idiopathic Pulmonary Fibrosis?
      • Drug-Class-Specific Trends
        • Antifibrotics
        • Connective Tissue Growth Factor Inhibitors
      • Alternative Market Scenarios
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
        • Role of Inflammation
      • Disease Progression
      • Disease Staging
      • Symptoms and Complications
        • Symptoms and Complications of Idiopathic Pulmonary Fibrosis
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Drug-Treated Prevalent Cases
        • Severity Stages
        • Comorbidity
    • Current Treatment Overview
      • Introduction
        • Key Findings
      • Diagnosis
        • Diagnosis of Idiopathic Pulmonary Fibrosis
        • Diagnostic Tests and Criteria
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antifibrotics
        • Tyrosine Kinase Inhibitors
        • Expert Insights on Pirfenidone and Nintedanib
        • Clinical Trial Results of Pirfenidone vs. Nintedanib
        • Other Medications Used to Treat Idiopathic Pulmonary Fibrosis
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Idiopathic Pulmonary Fibrosis
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Idiopathic Pulmonary Fibrosis
        • Connective Tissue Growth Factor Inhibitors
        • Recombinant Human Pentraxin-2
        • Autotaxin Inhibitors
        • αvβ6 Integrin Inhibitors
      • Early-Stage Pipeline Analysis
        • Notable Developments in the Early-Stage Pipeline for Idiopathic Pulmonary Fibrosis
        • Expert Insight
      • Development Discontinuations and Failures in Idiopathic Pulmonary Fibrosis
      • Symptomatic or Acute Therapies in Development for Idiopathic Pulmonary Fibrosis
        • Symptomatic or Acute Therapies Overview
        • ART-123
      • Patient Registries
        • Patient Organizations
      • Orphan Drug Designation
        • Orphan Drug Provisions: United States
        • Orphan Drug Provisions: Europe
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Idiopathic Pulmonary Fibrosis Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Akash Saini, PhD; Abey John, MPH
  • Akash Saini, is a lead analyst with the Infectious, Niche, and Rare Disease team at Decision Resources Group. Prior to joining Decision Resources Group, Saini was a postdoctoral fellow at the University of Massachusetts Medical School, where he studied mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS). He earned a in Biochemistry and Biotechnology from the International Centre for Genetic Engineering and Biotechnology, New Delhi, where he also studied the underlying disease mechanism in ALS, and an in Biotechnology from Jawaharlal Nehru University, New Delhi, where he studied the biophysical characteristics of amyloid formation.

  • Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Purchase Report

Recent reports: